Home >
Icotinib (Conmana)
Last Updated: 03/13/18
Status: Currently a NF2 Clinical Trial
| Trade Name: | Conmana |
|---|---|
| Synonyms: | Icotinib hydrochloride (BPI-2009H), 610798-31-7, Conmana, BPI-2009, UNII-9G6U5L461Q, BPI-2009H, CHEMBL2087361, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine, N-(3-ethynylphenyl)-7H,8H,10H,11H,13H,14H-1,4,7,10-tetraoxacyclododeca[2,3-g]quinazolin-4-amine, Icotinib(Lcotinib) |
| Pharmaceutical Company: | |
| Legal Status: | ℞ - Prescription, in China, Beijing |
| Administered By: | Pill - Oral |
| Tumor Target: | NF2 Vestibular Schwannoma, solid tumors |
| Protein Target: | Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor (EGFR-TKI) |
| Formula: | C22H22ClN3O4 |
| NF2 Trial: | Recruiting Trial: NCT02934256 |
| PubChem | CID 44609731 |
| ChemSpider | 28637803 |
Source
- Peng, Li. ClinicalTrials.gov. NIH - U. National Library of Medicine. "Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors" (2016) Clinical Trials.
Source: https://clinicaltrials.gov/ct2/show/NCT02934256 - Hu, Shaojing, et al. Bioorganic & medicinal chemistry letters "Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent
EGFR inhibitors." 22.19 (2012): 6301-6305.
Source: https://www.sciencedirect.com/science/article/pii/S0960894X12008189 | DOI: 10.1016/j.bmcl.2012.06.067
